Breast implants after mastectomy associated with very low risk of rare lymphoma: JAMA

Researchers have found in a new Columbia study that Breast implants after mastectomy associated with very low risk of developing  anaplastic large-cell lymphoma (ALCL), after reconstructive surgery.  Each year, about 12 cases are expected to occur per 1 million women who've had reconstructive surgery.

"The risk of developing ALCL is actually much lower than the risk of experiencing a relapse of breast cancer," says lead author Connor J. Kinslow, MD, a resident in radiation oncology at the Columbia University Vagelos College of Physicians and Surgeons.

"Based on our findings, we do not believe that women should be dissuaded from having implant-based breast reconstruction after mastectomy solely due to the risk of ALCL."

The new study was designed to provide women with accurate information about risk and is the first to look at rates of ALCL in breast cancer survivors who've had breast implants after mastectomy.

The researchers used a national cancer registry to identify 57,000 women who had undergone mastectomy with implant reconstruction for breast cancer or ductal carcinoma in situ (an early, noninvasive stage of breast cancer) between 2000 and 2018. The median follow-up time was seven years, and roughly 16,000 women were followed for at least 10 years.